Wireless communication authentication for medical monitoring device

This patent covers a handheld analyte-monitoring apparatus — in plain terms, a blood-glucose meter or similar device — that incorporates a power-efficient, authentication-gated wireless link to an external sensor. Claim 1 describes a concrete physical apparatus comprising a housing, a memory unit holding executable instructions, a monitor that analyzes fluid on a test strip, a transceiver, and a processor. The novel logic lies in the processor's behavior: it enables a sensor interface and searches for an external sensor while the user-interface (UI) capabilities tied to that interface are kept disabled; the search consists of transmitting a signal over a determined period. If no sensor is detected within that window, the device terminates transmission and disables the interface — a power-conservation and security gate. Only when a sensor is detected does it enable the UI capabilities, activate the external sensor, and determine analyte concentration. The abstract broadens this to short-range low-power wireless communication and energy-harvesting from received electromagnetic signals. The defining limitations are the disabled-UI-during-search state, the time-bounded transmission with automatic teardown, and the detection-triggered activation sequence.

The assignee is Abbott Diabetes Care Inc, with named inventors He Lei Lawrence and Marc B. Taub. The patent was granted in 2016. Its family of 11 members across 3 countries indicates focused, multi-jurisdiction prosecution rather than a sprawling global filing — consistent with protecting a specific feature within a larger product line. Forward citations stand at 9, which is modest. For a 2016 grant covering an incremental power-management/authentication mechanism, this likely reflects the narrow, implementation-specific scope rather than low relevance — it is a feature patent, not a platform claim that downstream filers must navigate around in volume.

Where this patent stands: This is a niche refinement within Abbott Diabetes Care's substantial continuous-glucose-monitoring (CGM) portfolio. It does not function as a foundational anchor — those roles belong to the early analyte-sensor and on-body-device filings (Abbott holds 6 patents totaling 1,035 citations in this set, plus the THERASENSE foundational lineage). Instead, US-9344777-B2 protects a specific energy- and security-conscious sensor-handshake behavior that plausibly underpins the wireless pairing flow in commercial reader/sensor products. It sits alongside the broader Abbott and Dexcom CGM patent estates rather than displacing them, and its value is defensive and product-specific: it fences a particular implementation of low-power sensor authentication that competitors building reader-to-sensor wireless links would otherwise be free to adopt.

The surrounding space is densely clustered around CGM and wireless analyte communication, and it is dominated by Dexcom Inc, which holds 16 patents and 2,500 citations in this set — by far the most active player among the nearest patents. Abbott Diabetes Care Inc (6 patents, 1,035 citations) and the foundational Therasense Inc lineage (1 patent, 3,588 citations — the genre's anchor filing) are the other principal forces, with Masimo Corporation (2 patents, 460 citations) present at the periphery. The technology concentration confirms how tight this cluster is: Switching & Selecting (H04Q) runs at 29.7× the corpus baseline, Healthcare IT (G16H) at 60.4×, and Medical Diagnosis & Surgery (A61B) at 21.3× — this is a narrow, heavily-worked intersection of medical sensing and wireless networking, not a broad field.

The closest related patents:

• US-10561349-B2 — Systems and methods for display device and sensor electronics unit communication (Dexcom Inc · 78 citations · 46-member family). Directly parallel: it governs the communication handshake between a sensor electronics unit and a display device, the same reader-to-sensor link problem the subject patent solves on the meter side.
• US-8844007-B2 — Systems and methods for processing and transmitting sensor data (Dexcom Inc · 50 citations · 23-member family). A core Dexcom transmission patent that frames the data-handling layer the subject patent's authentication sits beneath.
• US-8461985-B2 — Analyte monitoring system and methods (Abbott Diabetes Care Inc · 167 citations · 7-member family). Abbott's own higher-cited system-level filing; the subject patent reads as a feature-level companion to this estate.
• US-11109756-B2 — Intelligent wireless communications for continuous analyte monitoring (Dexcom Inc · 1 citation · 18-member family). A 2021 filing very close on point to the subject's wireless-link logic; its single citation makes it strategic IP the citation-weighted score under-rewards, and worth watching as Dexcom's continuation activity in this exact area.

Note one chart-vs-relevance caveat: Dexcom dominates the nearest patents — appearing on roughly half the closest results — yet ranks second to Therasense on the citation chart because Therasense's single 1998-era foundational patent (US-6175752-B1, 3,588 citations) carries outsized citation weight. The practical competitive density here is Dexcom and Abbott head-to-head. Filing activity has remained steady through the 2018–2025 window (with a 2020 peak of 6), indicating continued investment in wireless CGM communication rather than any decline.